Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,111 result(s) found for: Brain function. Displaying page 1 of 56.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-013128-22 Sponsor Protocol Number: HE 42/09 Start Date*: 2010-06-29
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from lung and breast tumors. A phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
    Medical condition: Patients with brain metastases from lung and breast tumors
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004244-37 Sponsor Protocol Number: 13HH1824 Start Date*: 2014-02-21
    Sponsor Name:Imperial College London | Imperial College NHS Healthcare Trust
    Full Title: The control of brain networks after traumatic brain injury: a neuroimaging and neuropsychological study of dopamine and cognition
    Medical condition: Traumatic Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004863 10060690 Traumatic brain injury LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002109-58 Sponsor Protocol Number: RSR13 RT-016 Start Date*: 2005-02-14
    Sponsor Name:ALLOS Therapeutics, Inc.
    Full Title: A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 (efaproxiral), in Women with Brain Metastases...
    Medical condition: Brain metastases from breast cancer
    Disease: Version SOC Term Classification Code Term Level
    4.0 10027453 4
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) HU (Completed) GB (Completed) LT (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005194-32 Sponsor Protocol Number: CRANIAL Start Date*: 2013-06-28
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer
    Medical condition: Brain metastasis secondary to HER2-negative breast cancer and NSCLC, not previously irradiated and not requiring immediate radiation.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059282 Metastases to central nervous system PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000661-12 Sponsor Protocol Number: OCTO_022 Start Date*: 2011-08-23
    Sponsor Name:University of Oxford
    Full Title: A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases
    Medical condition: Metastatic melanoma with brain metastases.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007350-35 Sponsor Protocol Number: ML 22203 Start Date*: 2009-07-17
    Sponsor Name:ROCHE
    Full Title: A single arm, open-label trial assessing the effect of Capecitabine (Xeloda®) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radio...
    Medical condition: Female breast cancer patients with progression of brain metastasis following WBRT and at least one measurable lesion in the brain (defined as any lesion >1 cm in longest dimension at MRI).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005247-10 Sponsor Protocol Number: ITCC-003-Tarceva/Roche MO 18461 Start Date*: 2005-07-29
    Sponsor Name:The University Hospitals of Leicester NHS Trust
    Full Title: Phase I study of TARCEVA (Erlotinib Hydrochloride, OSI-774) as a single agent in children with refractory and relapsed malignant brain tumours and in combination with irradiation in newly diagnosed...
    Medical condition: Refractory and relapsed malignant brain tumours and newly diagnosed brain stem glioma.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004596-31 Sponsor Protocol Number: NL62772 Start Date*: 2019-03-25
    Sponsor Name:UMC Utrecht
    Full Title: CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass
    Medical condition: Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010495 Congenital heart disease NOS LLT
    20.0 10029205 - Nervous system disorders 10067967 Brain injury PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007349-30 Sponsor Protocol Number: ML21873 Start Date*: 2009-04-15
    Sponsor Name:ROCHE
    Full Title: Open-label, phase II, randomized, comparative, multicentre trial of concurrent Whole Brain Radiation Therapy (WBRT) and capecitabine (Xeloda®) followed by maintenance capecitabine compared with sta...
    Medical condition: Female breast cancer patients with newly diagnosed CNS metastases with at least one brain lesion measuring ≥0.5 cm in longest dimension, who are not considered candidates for surgery or stereotacti...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001084-10 Sponsor Protocol Number: GEP 02/0801 Start Date*: 2008-11-21
    Sponsor Name:FNCLCC
    Full Title: A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer.
    Medical condition: Patient with non penetrated brain metastasis from HER2 positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003003-31 Sponsor Protocol Number: EORTC 26082 – 22081 Start Date*: 2009-12-01
    Sponsor Name:EORTC Headquarters
    Full Title: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a ra...
    Medical condition: patients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoter
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006153 Brain tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001453-31 Sponsor Protocol Number: CONMED3 Start Date*: Information not available in EudraCT
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: Automated pupillometry and NIRS-EEG to detect signatures of consciousness in acute brain injury after apomorphine and methylphenidate stimulation: A placebo-controlled, randomized, cross-over study
    Medical condition: We investigate the possible effects of commercially available apomorphine and methylphenidate on signatures of consciousness in patients admitted to the ICU with acute disorder of consciousness, us...
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029205 - Nervous system disorders 10013509 Disturbances in consciousness NEC HLT
    21.1 10029205 - Nervous system disorders 10067967 Brain injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000083-24 Sponsor Protocol Number: GCPL/RGN/02 Start Date*: 2007-06-07
    Sponsor Name:Regen Therapeutics PLC
    Full Title: A survey of efficacy of zolpidem in patients with brain injury including SPECT brain scans in selected patients
    Medical condition: Brain damage of any original cause, such as strokes, trauma, birth injury, post-viral infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056389 Brain damage LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2016-004974-16 Sponsor Protocol Number: IL1ra03 Start Date*: 2018-11-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST.
    Medical condition: We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    20.1 10029205 - Nervous system disorders 10051288 Central nervous system inflammation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005476-40 Sponsor Protocol Number: A5961166 Start Date*: 2007-02-20
    Sponsor Name:Pfizer Inc
    Full Title: PHASE 2 SINGLE-ARM, OPEN LABEL STUDY OF IRINOTECAN IN COMBINATION WITH TEMOZOLOMIDE IN CHILDREN WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA AND IN CHILDREN WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA
    Medical condition: children with recurrent or refractory medulloblastoma and newly diagnosed high-grade glioma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061030 Brain tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DK (Completed) IT (Prematurely Ended) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002714-11 Sponsor Protocol Number: EORTC 22033-26033 Start Date*: 2005-06-06
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study
    Medical condition: Histologically proven low-grade glioma ♦ Astrocytoma WHO grade II (gemistocytic, fibrillary and protoplasmatic) ♦ Oligoastrocytoma WHO grade II ♦ Oligodendroglioma WHO grade II
    Disease: Version SOC Term Classification Code Term Level
    7.1 10025783 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Completed) HU (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005614-34 Sponsor Protocol Number: INFI-21-07 Start Date*: Information not available in EudraCT
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A Phase 1b/2, Multicenter, Open-Label Study of Oral Infigratinib in Pediatric Subjects with Advanced Solid and Central Nervous System (CNS) Tumors (Phase 1b) and in Subjects with Recurrent or progr...
    Medical condition: Advanced solid and CNS tumors with selected FGFR1-3 mutations or fusions/rearrangements, inclusive of recurrent or progressive low-grade glioma (LGG) with selected FGFR1-3 mutations or fusions/rear...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10025783 Malignant neoplasm of brain LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005912-28 Sponsor Protocol Number: EGF107671 Start Date*: 2007-04-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Study EGF107671 – a Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radi...
    Medical condition: Brain metastases from ErbB2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005735-79 Sponsor Protocol Number: UC-BCG-2011 Start Date*: 2021-09-02
    Sponsor Name:UNICANCER
    Full Title: Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression
    Medical condition: HER2-positive metastatic breast cancer with isolated brain progression (defined as new or progressive brain metastases with stable or responding systemic disease) after complete local treatment.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000889-36 Sponsor Protocol Number: H6Q-MC-S020 Start Date*: 2006-08-10
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer
    Medical condition: brain metastastases of non-small or small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Completed) DK (Completed) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 08:31:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA